您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Cefotaxime
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cefotaxime
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cefotaxime图片
CAS NO:63527-52-6
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
100mg电议
250mg电议
500mg电议

产品介绍
Cefotaxime是第三代头孢类抗生素和耐内酰胺酶的头孢菌素,具有广泛的抗革兰氏阳性菌和革兰氏阴性菌的作用。
Cas No.63527-52-6
别名头孢噻肟酸,Cefotaxim; HR-756
Canonical SMILESO=C(C(N12)=C(COC(C)=O)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)O
分子式C16H17N5O7S2
分子量455.47
溶解度DMSO: 250 mg/mL (548.88 mM)
储存条件Store at 2-8℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Cefotaxime, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria[1][2][3][4][2].

Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6[4].

The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens[4]. Animal Model: Female, specific pathogen free, 8-week-old BALB/c mice[4].

[1]. Hee-Chang Jang, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One. 2014 Jun 30;9(6):e101118. [2]. Woodfield JC, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9. [3]. Scholz H, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7. [4]. Gums JG, et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother. 2008 Jan;42(1):71-9. [5]. E L Francke, et al. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. Am J Med. 1981 Sep;71(3):435-42.